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Abstract 
Background: The sodium–glucose cotransporter 2 inhibitor, dapagliflozin, has been shown to improve diabetic 
control and reduce blood pressure in patients with type 2 diabetes mellitus. Its effects on micro- and macrovascular 
structure and function have not yet been reported.
Methods: This was a prospective, single-centre, placebo-controlled, double-blind, randomised crossover phase IIIb 
study conducted between March 2014 and February 2015. After a 4-week run-in/washout phase, patients (N = 59) 
received 6 weeks of either dapagliflozin 10 mg or placebo once daily. They then underwent a 1-week washout before 
crossing over to the other treatment. Changes in retinal capillary flow (RCF) and arteriole remodelling were evaluated 
using scanning laser Doppler flowmetry, while micro- and macrovascular parameters in the systemic circulation were 
assessed using pulse wave analysis.
Results: Six weeks of dapagliflozin treatment resulted in improvements in diabetes control, including blood glucose 
and insulin resistance, and reduced office and 24-h ambulatory blood pressure values. RCF decreased from 324 AU at 
baseline to 308 AU after treatment with dapagliflozin (p = 0.028), while there was little difference after the placebo 
(318 AU; p = 0.334). Furthermore, the arteriole remodelling that was seen after the placebo phase was not evident 
after the dapagliflozin phase. Central systolic and diastolic blood pressure values were significantly lower after 6 weeks 
of dapagliflozin, by 3.0 and 2.2 mmHg, respectively (p = 0.035 and 0.020, respectively vs. baseline).
Conclusions: Six weeks of dapagliflozin treatment resulted in numerous beneficial effects. In addition to achieving 
superior diabetes control and blood pressure, parameters associated with the early stages of vascular remodelling 
were also improved.
Trial registration http://www.clinicaltrials.gov (NCT02383238)
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Background
The majority of the increased mortality risk associated 
with type 2 diabetes is a result of cardiovascular disease 
(CVD). This demonstrates the importance of not only 
treating hyperglycaemia, but also managing the other 
contributory risk factors, including hypertension and 
dyslipidemia [1]. Early changes to the vasculature in 
patients with type 2 diabetes are characterised by hyper-
perfusion of microvessels such as those in the eye and 
kidney, vascular remodelling, and arterial stiffening [2]. 
Such changes can be identified using non-invasive tech-
niques, even prior to the development of symptoms. The 
retinal microvasculature can be analysed using scanning 
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laser Doppler flowmetry (SLDF), which provides capil-
lary flow rates and visualisation of vascular structure [3, 
4]. Pulse wave analysis, on the other hand, allows evalu-
ation of the compliance of larger vessels through meas-
urement of among others, central pulse pressure (PP), 
augmentation pressure and index [5–7]. Arterial stiffen-
ing and an increased amplitude of wave reflection attrib-
utable to peripheral vasoconstriction lead to an earlier 
return and a higher amplitude of arterial wave reflection 
in the aorta. This results in an inadequate increase in sys-
tolic blood pressure (BP) and a relative decrease in dias-
tolic BP, thus increasing central PP at any given value of 
mean arterial pressure. Central augmentation index (AIx) 
is a direct measure of pulse wave reflection. We could 
previously shown in a non-diabetic cohort across a wide 
range of BP that both central PP and central AIx corre-
lated well with wall-to-lumen ratio (WLR) of retinal arte-
rioles [8].
Studies evaluating the efficacy of anti-diabetic drugs 
rarely assess their effect on blood vessels, despite the prog-
nostic significance. Ott et al. demonstrated that the dipep-
tidyl peptidase (DPP)-4 inhibitor, saxagliptin, was able to 
reduce retinal capillary flow (RCF) and improve central 
haemodynamics compared to placebo during a 6-week 
treatment period [2]. Reductions in arterial stiffness have 
been demonstrated during treatment with other DPP-4 
inhibitors and with pioglitazone added to metformin [9, 
10].
Sodium–glucose cotransporter 2 (SGLT2) inhibitors 
are oral anti-diabetic drugs that work by decreasing re-
absorption of glucose in the renal proximal tubule [11]. 
They have been shown to reduce glycosylated haemoglo-
bin (HbA1c) and fasting plasma glucose (FPG) levels, as 
well as to induce weight loss and decrease BP [12–14]. 
This latter effect is likely caused by the simultaneous 
excretion of sodium, as well as being a consequence of 
the weight loss. Cherney et  al. showed that, in patients 
with type 1 diabetes, empagliflozin resulted in a reduc-
tion in arterial stiffness over the course of an 8-week 
study [15]. Chilton et al. performed a post hoc analysis of 
five phase III trials involving patients with type 2 diabe-
tes being treated with empagliflozin [16]. They identified 
significant reductions in PP and mean arterial pressure as 
markers of arterial stiffness and resistance, respectively, 
compared to placebo. Dapagliflozin is another SGLT2 
inhibitor; however, while its anti-hyperglycaemic and 
anti-hypertensive effects have been demonstrated in a 
number of clinical trials [12] as well as in a real-world 
care setting [17], there are no available data regarding 
associated vascular changes.
The present study was performed in order to evaluate 
the micro- and macrovascular changes that accompany 
dapagliflozin treatment in patients with type 2 diabetes. 
Using a combination of non-invasive analytical tech-




The study was a prospective, randomised, double-blind, 
placebo-controlled, cross-over phase IIIb trial performed 
at the Clinical Research Center of Erlangen-Nuremberg, 
Germany. Between March 2014 and February 2015, 
patients with type 2 diabetes were recruited from the 
University outpatient clinic, through physician referrals, 
and through the use of newspaper advertisements. After 
a run-in/washout period (2 weeks for patients not receiv-
ing anti-diabetic treatment; 4 weeks for patients treated 
with anti-diabetic medication), patients were randomised 
to receive either once-daily oral dapagliflozin 10  mg or 
placebo through use computer generated algorithm for 
this single center study (Fig. 1). After 6 weeks, there was 
a 1-week washout period, and then the patients crossed 
over to the other treatment.
The study was approved by the Ethics Committee of 
the University of Erlangen (IRB/IEC) on the 7th Febru-
ary 2014. Furthermore, it was performed in accordance 
with the Declaration of Helsinki. All patients provided 
written informed consent prior to inclusion in the study. 
The study was registered at http://www.clinicaltrials.gov 
(NCT02383238).
Study population
Patients were included in the study if they had type 2 
diabetes and were between 18 and 70 years of age. Indi-
viduals were excluded if they had any other form of dia-
betes, were being treated with insulin or more than one 
oral anti-diabetic drug, were being treated with any 
medication with loop diuretics, had a HbA1c level ≥10% 
(86  mmol/mol), had a FPG level  >240  mg/dl, had 
BP  ≥180/110  mmHg, had an estimated glomerular fil-
tration rate (eGFR)  <60  ml/min/1.73  m2, or had a body 
mass index (BMI) >40 kg/m2 or suffered from cataract or 
glaucoma.
Endpoints
The primary endpoint was the effect of dapagliflozin 
compared to placebo on RCF and arteriole remodel-
ling after 6  weeks of treatment. Secondary endpoints 
included the effects on the micro- and macrovascular 
parameters of the systemic circulation, including central 
BP, heart rate, and augmentation pressure, as measured 
by pulse wave analysis. RCF after flicker light exposure 
was also evaluated serving as a test of vasodilatory capac-
ity of the retinal vascular bed. Other clinical character-
istics that were measured were office BP (systolic [SBP] 
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and diastolic [DBP]), 24-h ambulatory SBP and DBP, 
blood glucose levels, and lipid levels.
Clinical parameters
Demographic data were recorded at the first visit, prior to 
the washout period. At the randomisation visit, a fasting 
blood sample was taken in order to measure HbA1c, FPG, 
lipid levels, and other biochemical safety parameters (e.g. 
creatinine, liver enzymes). After consuming a standardised 
breakfast, further blood was taken to allow measurement 
of post-prandial glucose (PPG). For evaluation of insulin 
resistance, the homogenous model assessment (HOMA) 
index was calculated [18]. Office BP and heart rate meas-
urements were taken in a seated position after 5  min of 
rest. Twenty-four hour ambulatory BP was measured in 
parallel with Spacelab 90,207 (Spacelabs Health Care. WA, 
USA). Measurements were taken every 15 min throughout 
the day and every 30 min during the night.
SLDF was performed using a Heidelberg retina flow-
meter in combination with semiautomatic analysis using 
Software 4.0 (Welzenbach & Schmieder) [4]. This tech-
nique was used to measure microvascular parameters, 
including RCF, RCF after flicker light exposure (10  Hz; 
Photo Stimulator 750, Siemens-Elema AB, Sweden), and 
arteriole dimensions. WLR and wall cross sectional area 
were calculated in standard manner [2, 4]. Macrovascular 
parameters were evaluated through pulse wave analysis 
using the SphygmoCor™ system (AtCor Medical, Sydney, 
Australia). The obtained central arterial waveforms were 
used to calculate central PP, augmentation pressure, and 
AIx.
All biochemical, microvascular, and macrovascu-
lar analyses were repeated after each of the two 6-week 
treatment periods. Any adverse events that occurred dur-
ing the study were recorded.
Statistics
The sample size was calculated for the primary endpoint 
of RCF changes. Using data acquired from a similar study 
[2], the within standard deviation of RCF was estimated 
to be 63 AU. In order to show a decrease of 25 AU after 
dapagliflozin as opposed to placebo after 6  weeks, for 
α = 0.05 and β = 0.80, the required number of patients 
was calculated to be 52. From our previous experience, 
the drop-out rate was estimated to be 15–20% [2]; there-
fore, we aimed to randomise 62 patients.
Data are presented as absolute values and percent-
ages or means with standard deviation (SD). Statistical 
Fig. 1 Study design. Micro- and macrovascular parameters assessed at visits 0, 2, and 5. Clinical characteristics assessed at all visits
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significance of differences between the test drug and the 
placebo was determined using a paired t test, assuming 
normal distribution. Statistical analysis was performed 
using SPSS release 19.0.
Results
Patients
A total of 67 patients were screened, with 62 undergoing 
randomisation, 31 to initial dapagliflozin and 31 to ini-
tial placebo treatment. Of these, 59 patients completed 
the study and had all the required SLDF and pulse wave 
analysis data available (full analysis set; FAS). The mean 
age of the FAS was 60.3  years and 39.0% were female 
(Table 1). The mean duration of diabetes was 5.54 years 
and the mean HbA1c level was 6.67% (49 mmol/mol).
Clinical characteristics after 6 weeks
After 6  weeks of treatment, the HbA1c level had not 
changed significantly from baseline for either the dapa-
gliflozin or placebo, although the final value was slightly 
lower for the test drug (6.62% [49 mmol/mol] vs. 6.79% 
[51 mmol/mol]; p < 0.001) (Table 2). In terms of FPG, the 
level after dapagliflozin treatment decreased by 18 mg/dl 
(p  <  0.001), while that after the placebo did not change 
from baseline. This resulted in a significantly lower FPG 
value after the dapagliflozin in comparison to after the 
placebo (114 vs. 135  mg/dl; p  <  0.001). Although both 
the dapagliflozin and placebo resulted in decreases in 
PPG, the final values after 6  weeks of treatment were 
significantly lower for the dapagliflozin (154 vs. 180 mg/
dl; p  <  0.001). The level of insulin was lower after the 
dapagliflozin treatment than after the placebo (9.7 vs. 
12.9 mU/l; p = 0.002), having decreased by 2.3 mU/l on 
treatment with dapagliflozin. HOMA index of insulin 
resistance also changed during each treatment, result-
ing in a lower value after dapagliflozin and a higher value 
after placebo. This led to significantly different levels after 
the 6 weeks (2.77 vs. 4.48 for dapagliflozin and placebo, 
respectively; p < 0.001).
Office SBP decreased by 4  mmHg from baseline after 
treatment with dapagliflozin, but only 1  mmHg after 
placebo. DBP was also lower after the drug treatment, 
but only by 2 mmHg. Twenty-four hour ambulatory BP 
monitoring also demonstrated reductions in both systolic 
and diastolic measurements after dapagliflozin treat-
ment, resulting in significantly lower values compared to 
placebo (SBP: 126 vs. 129 mmHg, p = 0.021; DBP: 75 vs. 
77 mmHg, p = 0.027). Lipid levels remained stable dur-
ing the study, with the only difference being lower triglyc-
erides after dapagliflozin treatment than after placebo 
(146 vs. 159 mg/dl; p = 0.043).
Microvascular and macrovascular parameters after 6 weeks 
of treatment
Retinal capillary flow was lower after 6  weeks of dapa-
gliflozin treatment compared to baseline (308 vs. 318 
AU; p = 0.028), while there was no notable change after 
6 weeks of placebo (Table 3). RCF after flicker light did 
not change greatly after either treatment. Mean outer 
arteriole diameter (AD) remained stable, while there were 
only non-significant changes in arteriole lumen diameter 
(LD). However, the WLR ([AD–LD]/LD) after 6  weeks 
of placebo, an indicator of early vascular remodelling, 
was slightly higher than at baseline (+0.03; p =  0.034), 
whereas no such change occurred with dapagliflozin 
treatment. Arteriolar wall cross sectional area after dapa-
gliflozin treatment did not change (p = 0.800). The same 
was found for the placebo group (p = 0.210).
Slight changes in central SBP and DBP values from 
baseline led to a lower PP after 6  weeks of dapagliflo-
zin treatment compared to 6  weeks of placebo (40.9 vs. 
43.6 mmHg; p = 0.05). Any changes in the placebo phase 
were not seen. There were no changes in augmentation 
pressure and index during the study. Furthermore, post-
treatment values for central heart rate, augmentation 
pressure and index did not vary between dapagliflozin 
and placebo.
Table 1 Patient characteristics at baseline
N = 59
BMI body mass index, HbA1c glycosylated haemoglobin, HOMA homeostatic 
model assessment, LDL-C low-density lipoprotein cholesterol, HDL-C high-
density lipoprotein cholesterol
a  A standardised breakfast was given
Mean ± SD or n/N (%)
Age (years) 60.3 ± 7.6
Female 23/59 (39.0)
Weight (kg) 87.4 ± 13
Height (cm) 171 ± 11
BMI (kg/m2) 29.9 ± 4.3
Mean duration of diabetes (years) 5.54 ± 4.9
HbA1c 6.67 ± 0.7% (49 mmol/mol)
Glucose
Fasting (mg/dl) 132 ± 28
Postprandiala (mg/dl) 178 ± 66
Fasting Insulin (mU/l) 12.1 ± 7.4
HOMA index 4.02 ± 2.8
Office blood pressure (mmHg)
Systolic 130 ± 14
Diastolic 79 ± 9
Lipids (mg/dl)
LDL-C 143 ± 32
HDL-C 48.2 ± 11
Total cholesterol 207 ± 39
Triglycerides 149 ± 66
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Discussion
Six weeks of treatment with dapagliflozin improved dia-
betic control and reduced BP in comparison to placebo. 
Furthermore, the drug was capable of reducing hyper-
perfusion of retinal capillaries and minimising arteriole 
remodelling, factors that contribute to the progression 
of diabetic retinopathy. Pulse wave analysis additionally 
showed that dapagliflozin reduced markers of arterial 
stiffness, demonstrating the multiple beneficial effects of 
the drug.
Clinical characteristics
There was little change in HbA1c on treatment with 
either placebo or dapagliflozin, which is likely due to the 
short period of time (6 weeks) over which the study was 
carried out. However, the slight increase for placebo and 
slight decrease for dapagliflozin may indicate an effect 
of the drug, particularly as FPG and PPG were both 
significantly lower after the 6  weeks of dapagliflozin 
treatment. Chronic hyperglycaemia results in reduced 
insulin sensitivity and reduced β-cell function [19]. In 
the present study, insulin resistance, as determined by 
calculating the HOMA index, was significantly lower 
after 6  weeks of dapagliflozin treatment, while it was 
slightly higher after 6  weeks of placebo. This finding 
is in agreement with that reported by Mudaliar et  al., 
where 12  weeks of dapagliflozin treatment resulted in 
increased insulin sensitivity, while the placebo did not 
cause a change [20].
Dapagliflozin treatment has previously been shown to 
reduce BP in patients with type 2 diabetes, likely as a result 
of its natriuretic and diuretic effects [11]. In a multi-cen-
tre study it was shown that the effect on BP was greater in 
patients who needed a diuretic-like effect to optimize BP 
control [21]. In the present study, we observed a decrease 
in office SBP by approximately 4 mmHg after 6 weeks of 
dapagliflozin treatment, which is of a comparable mag-
nitude to those reported in other studies [11]. As a more 
accurate measure of BP, we also investigated the effect on 
ambulatory BP values, and found a significant decrease 
in both SBP and DBP. Therefore, our data corroborate 
those previously reported, providing further evidence of 
the additional benefit of dapagliflozin beyond its glucose-
lowering ability.
Table 2 Clinical characteristics after 6 weeks of dapagliflozin treatment (mean ± SD)
N = 59
BMI body mass index, HbA1c glycosylated haemoglobin, HOMA homeostatic model assessment, LDL-C low-density lipoprotein cholesterol, HDL-C high-density 
lipoprotein cholesterol
a  6.79% = 51 mmol/mol; 6.62% = 49 mmol/mol
b  A standardised breakfast was given
Placebo Dapagliflozin p value placebo 
vs. dapagliflozin
Absolute value  
(change from baseline)
p value vs.  
baseline
Absolute value  
(change from baseline)
p value vs. 
baseline
HbA1c (%)a 6.79 ± 0.8 (0.12 ± 0.5) 0.064 6.62 ± 0.7 (−0.05 ± 0.3) 0.224 <0.001
Glucose
Fasting (mg/dl) 135 ± 32 (+2.3 ± 18) 0.325 114 ± 19 (−18.3 ± 16) <0.001 <0.001
Postprandial (mg/dl)b 180 ± 67 (+1.2 ± 31) 0.766 154 ± 46 (−24.8 ± 40) <0.001 <0.001
Insulin (mU/l) 12.9 ± 10.6 (+0.8 ± 5.5) 0.276 9.7 ± 5.4 (−2.4 ± 4.1) <0.001 0.002
HOMA index 4.48 ± 4.7 (+0.46 ± 2.5) 0.157 2.77 ± 1.7 (−1.25 ± 1.8) <0.001 0.001
BMI (kg/m2) 29.9 ± 4.2 (+0.0 ± 0.7) 0.846 29.5 ± 4.1 (−0.30 ± 0.7) <0.001 <0.001
Office blood pressure
Systolic (mmHg) 129 ± 13 (−1 ± 10) 0.340 126 ± 12 (−4 ± 12) 0.015 0.102
Diastolic (mmHg) 79 ± 9 (0 ± 6) 0.984 78 ± 9 (−1 ± 6) 0.058 0.113
Heart rate (bpm) 67.8 ± 9.6 (−1.3 ± 6.2) 0.123 68.2 ± 10.6 (−0.8 ± 6.5) 0.332 0.659
24-h ambulatory blood pressure
Systolic (mmHg) 129 ± 11 (−1 ± 10) 0.682 126 ± 11 (−3 ± 10) 0.010 0.021
Diastolic (mmHg) 77 ± 7 (0 ± 6) 0.765 75 ± 8 (−2 ± 6) 0.024 0.027
Heart rate (bpm) 75.7 ± 9.5 (+1.4 ± 6.8) 0.172 74.1 ± 7.6 (−0.8 ± 6.0) 0.351 0.132
Lipids (mg/dl)
LDL-C 142 ± 31 (−1 ± 23) 0.688 144 ± 31 (+1 ± 21) 0.808 0.478
HDL-C 48.5 ± 11 (+0.3 ± 4.8) 0.607 48.5 ± 12 (+0.4 ± 4.4) 0.541 0.954
Total cholesterol 207 ± 37 (0 ± 30) 0.937 209 ± 38 (+2 ± 26) 0.584 0.657
Triglycerides 159 ± 100 (+10 ± 91) 0.394 146 ± 74 (−3 ± 63) 0.684 0.043
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Microvascular variables
Microvascular complications of type 2 diabetes are 
known to be associated with hyperglycaemia, with the 
UKPDS demonstrating that a 1% decrease in HbA1c 
resulted in a 37% reduction in the risk of a microvas-
cular complication [22]. There is intensive crosstalk 
between the mechanisms by which high glucose levels 
contribute to these problems, with many details remain-
ing unclear. The early stages of diabetic vasculopathy are 
characterised by vessel hyperperfusion [23]. In patients 
with poorly controlled type 1 diabetes and background 
retinopathy, Grunwald et  al. found total retinal volu-
metric blood flow to be 23% higher than that considered 
normal [24]. In a comparison with patients without dia-
betes, Patel et  al. reported higher blood flow and larger 
vessel diameter for diabetic patients with signs of retin-
opathy [25]. Similar changes are observed in the micro-
vascular renal bed, namely renal hyperperfusion and 
glomerular hyperfiltration. This elevated blood flow is 
likely to cause vascular damage through increasing shear 
stress, causing endothelial dysfunction, basement mem-
brane disruption, and extracellular matrix remodelling 
[23, 26]. Decreasing hyperperfusion would therefore 
be a significant advantage of any anti-diabetic therapy. 
In the present study, RCF was found to be significantly 
lower after 6 weeks of treatment with dapagliflozin, while 
there was little change after placebo treatment. There 
could be a number of factors that contributed to this 
improvement. Firstly, the glucose-lowering effect of the 
drug could have directly reduced the blood flow. Indeed, 
Pemp et al. reported increased RCF in patients with type 
1 diabetes prior to their morning insulin injection, and 
that this normalised once glucose levels had been stabi-
lised [27]. In patients with type 2 diabetes, we found that 
RCF after 6 weeks of treatment with saxagliptin was sig-
nificantly lower than after 6 weeks of placebo, with this 
being alongside superior glucose lowering [2]. “In con-
trast, glucagon-like peptide-1 (GLP-1) therapy, but also 
sitagliptin, had no effect on capillary perfusion (assessed 
by nailfold skin capillary videomicroscopy) in patients 
with type 2 diabetes, suggesting that GLP-1 based ther-
apies in glucose are not mediated through microvas-
cular responses [28]. These data contrast our previous 
results with saxagliptin [2], other favorable observations 
with linagliptin [29], and the pathophysiologic rationale 
that multiple advantageous effects on vascular function 
Table 3 Microvascular and macrovascular parameters after 6 weeks
N = 59
AU arbitrary units, BP blood pressure
a  Normalised to a heart rate of 75 bpm








p value vs. 
baseline
Microvascular
Retinal capillary flow (AU) 324 ± 84 318 ± 87 (−6 ± 45) 0.334 308 ± 78 (−16 ± 53) 0.028 0.157
Retinal capillary flow after 
flicker, (AU)
351 ± 96 352 ± 101 (+2 ± 65) 0.838 344 ± 115 (−7 ± 84) 0.525 0.477
Outer arteriole diameter 
(µm)
109 ± 11 109 ± 12 (+1 ± 8) 0.599 109 ± 12 (+1 ± .9) 0.572 0.893
Arteriole lumen diameter 
(µm)
79.6 ± 7.6 79.0 ± 7.8 (-0.7 ± 6.1) 0.435 80.4 ± 7.8 (+0.7 ± 6.5) 0.410 0.074
Wall/lumen ratio 0.36 ± 0.1 0.39 ± 0.1 (+0.03 ± 0.1) 0.034 0.36 ± 0.1 (+0.01 ± 0.1) 0.524 0.086
Wall thickness (µm) 14.5 ± 3.4 15.1 ± 3.6 (+0.6 ± 3.1) 0.149 14.5 ± 3.3 (0.0 ± 3.1) 0.981 0.096
Wall cross section area (µm2) 4338 ± 1291 4531 ± 1373 (+194 ± 1121) 0.210 4378 ± 1331 (+41 ± 1176) 0.800 0.231
Macrovascular
Central systolic BP (mmHg) 121 ± 13 121 ± 13 (0 ± 11) 0.756 118 ± 11 (−3 ± 11) 0.035 0.084
Central diastolic BP (mmHg) 79 ± 8 77 ± 8 (−2 ± 7) 0.050 77 ± 7 (−2 ± 7) 0.020 0.951
Central pulse pressure 
(mmHg)
42.1 ± 11 43.6 ± 11 (+1.5 ± 8) 0.185 40.9 ± 11 (−1.1± 10) 0.405 0.050
Central heart rate (bpm) 63.9 ± 8.8 63.2 ± 7.5 (−0.7 ± 5.8) 0.398 62.3 ± 7.9 (−1.6 ± 4.5) 0.011 0.359
Augmentation pressure 
(mmHg)
12.8 ± 5.8 13.3 ± 6.4 (+0.4 ± 3.6) 0.392 12.9 ± 6.0 (+0.1 ± 4.0) 0.918 0.536
Augmentation index 29.3 ± 7.9 29.3 ± 8.3 (0.0 ± 5.1) 1.0 30.1 ± 8.4 (+0.9 ± 5.0) 0.213 0.372
Augmentation index @75a 24.0 ± 7.3 23.6 ± 8.1 (−0.4 ± 4.6) 0.556 24.1 ± 8.7 (+0.1 ± 4.6) 0.929 0.603
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structure by GLP-1 based therapies have been demon-
strated for patients with type 2 diabetes [30].
As well as affecting RCF, dapagliflozin treatment 
appeared to prevent changes to the structure of the reti-
nal arterioles. While no significant difference in vessel 
dimensions were found after the dapagliflozin period 
compared to baseline, the arteriole wall cross-sectional 
area and the WLR were both increased after the placebo 
period. An increased WLR and cross-sectional area are 
characteristic of the vascular hypertrophy seen in type 
2 diabetes [31]. Our findings may, therefore, indicate a 
positive effect of the dapagliflozin in preventing micro-
vascular remodelling. This is likely to be partly due to 
the aforementioned reduction in blood flow as a result of 
the glucose-lowering ability of the drug. Sub-endothelial 
fibronectin deposition has been shown to be induced by 
non-laminar flow conditions [32]. This, in turn, would 
likely alter smooth muscle cell behaviour, potentially 
resulting in increased proliferation and matrix synthesis 
[33]. Other glucose-independent effects of the dapagli-
flozin may also have contributed to preventing arteriole 
wall thickening. Elevated 24-h SBP has been shown to be 
independently associated with a higher WLR of retinal 
arterioles [34]. In the present study, this parameter was 
lower after 6 weeks of dapagliflozin treatment compared 
to baseline. Therefore, the reduction in BP may have had 
a protective effect against wall remodelling.
Macrovascular variables
Dapagliflozin treatment lowered central SBP, resulting 
in a reduced PP. On the other hand, while central DBP 
was lower after treatment with the placebo, there was 
no change in the central SBP. This resulted in a small but 
non-significant increase in pulse pressure. These data 
indicate that the dapagliflozin therapy caused a slight 
decrease in the stiffness of the aorta and its most proxi-
mal branches. The finding of a significant change in stiff-
ness after such a short period of treatment is encouraging 
and reflects functional changes (i.e. vascular tone, archi-
tecture of vascular smooth muscle cell layers) rather than 
structural ones (i.e. regression of vascular hypertrophy 
or fibrosis). A number of studies have linked increased 
central PP to CV morbidity and mortality [35]. This is of 
particular concern for individuals with type 2 diabetes, 
who are already at increased risk of CV complications 
and are more likely to display increased arterial stiffness 
[36, 37]. Similar to the present study, a number of other 
publications have reported decreases in arterial stiffness 
on treatment with anti-diabetic therapy. Duvnjak et  al. 
found that the two DPP-4 inhibitors, sitagliptin and vild-
agliptin, caused gradual decreases in AIx and central SBP 
in patients with type 2 diabetes over 12  weeks of treat-
ment [9], while Ott et  al. demonstrated lower central 
SBP after 6  weeks of treatment with saxagliptin [2]. In 
a cohort of patients with type 1 diabetes, Cherney et al. 
demonstrated decreases in aortic and carotid AIx from 
baseline after 8  weeks of empagliflozin treatment [15]. 
Chilton et al. performed a post hoc analysis of data com-
bined from a number of trials involving patients with 
type 2 diabetes, and found that empagliflozin signifi-
cantly reduced PP and mean arterial pressure compared 
to placebo [16].
In combination with our work on dapagliflozin, the 
positive results demonstrate that SGLT2 inhibitors are 
beneficial for decreasing arterial wall stiffness in patients 
with type 2 diabetes. The mechanism(s) by which these 
drugs produce these effects are multifaceted. The blood 
glucose-lowering effect is likely to be one factor. Hyper-
glycaemia and insulin resistance result in endothelial 
dysfunction, suppression of nitric oxide synthesis, and 
production of reactive oxygen species, which are all 
thought to contribute to arterial stiffening [38, 39]. Sch-
ram et  al. found lower total systemic arterial compli-
ance not only for patients with type 2 diabetes, but also 
for subjects with impaired glucose metabolism, in com-
parison to those with normal glucose metabolism [36]. 
Rubin et al. found a correlation between hyperglycaemia 
and markers of arterial stiffness, which held true when 
considering only the patients without diabetes [40]. The 
BP-lowering effect of SGLT2 inhibitors is also likely to 
contribute to the observed decreases in arterial stiffness. 
Although, a decrease in BP as a result of decreased arte-
rial stiffness cannot be ruled out [41].
Limitations
The main limitation to this study is its length; however, 
in the absence of other anti-diabetic therapies, it would 
not be ethical to administer a placebo for a longer period 
of time. Further limitations are the small sample size and 
that findings cannot be extrapolated to type 2 diabetes in 
general, since patients above 70 years were excluded from 
the study.
Conclusions
Six weeks of treatment with the SGLT2 inhibitor, dapagli-
flozin, resulted in improved diabetic control and reduced 
ambulatory BP. While these findings have been demon-
strated previously, we additionally showed that the drug 
was capable of reducing hyperperfusion of retinal capil-
laries and arteriole remodelling, factors that contribute 
to the progression of diabetic retinopathy. Furthermore, 
dapagliflozin treatment appeared to reduce arterial stiff-
ness, as indicated by lower central PP. Although the 
observed effects were small, they demonstrate the multi-
ple advantageous effects on vascular function and struc-
ture by dapagliflozin for patients with type 2 diabetes.
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